Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress.
“As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,

Related Keywords

Vienna , Wien , Austria , Bykate Burba , Arunj Sanyal , Heather Biele , Rohit Loomba , Virginia Commonwealth University , International Liver Congress , California San Diego School , New England Journal , Published June ,